The document details research on the synthesis and biological evaluation of radiolabeled curcumins and their ruthenium-arene complexes for applications in Alzheimer's disease and cancer treatment. It outlines the chemical processes involved in creating the 123I-labeled curcumin and the characterization of ruthenium complexes, while emphasizing their reduced effectiveness compared to natural curcumin. Future studies are suggested to further investigate the biodistribution and bioaccumulation of these compounds in vivo.